Fertilis is modernizing fertility treatment with micro-medical devices that mimic nature, automate IVF, and improve outcomes for patients and practitioners.
After decades of research and clinical practice, an IVF cycle is still more likely to fail than succeed.
In the US, infertility affects
14,000,000
and only 1% will have a child through IVF this year
Globally, infertility affects more than
145,000,000
and only about 0.7% will have a child through IVF this year
About Fertilis
Fertilis is on a mission to eliminate infertility.
Fertility rates are falling globally. Sperm counts are halving every generation. IVF clinics cannot keep up with the demand for treatment. After 40 years of clinical practice, an IVF cycle is still more likely to fail than succeed. The science is brilliant, but the technology is elementary.
Fertilis is building ground-breaking medical technology that transforms IVF. Our micro-fertility devices remove the risk and variability from IVF treatment, reduce the stress on both embryos and embryologists, and increase success rates for patients. The typical IVF patient needs three cycles of IVF to become pregnant. A patient treated with a Fertilis device only needs two.
Decreasing stress on
Our devices mimic nature and automate the IVF procedure. The result?
Less pressure for embryologists. Reduced stress for embryos. Improved outcomes for patients.
Our Devices
Micro-medical devices that change lives
By harnessing cutting-edge 3D printing techniques, Fertilis has developed micro-fertility devices– with features smaller than the width of a human hair– that enhance and automate the IVF process. A costly, time-sensitive, and error-prone process, IVF is fraught with risk and variability, with success rates ranging widely from clinic to clinic.
Our devices standardize and automate the IVF procedure, ensuring all patients have access to the best treatment possible and the greatest opportunity for a successful result.
microIVF triples success rates per IVF cycle. microICSI doubles lab capacity, reduces treatment costs, and improves patient outcomes.
microICSI
Male infertility is responsible for half of infertility cases worldwide. microICSI reduces the amount of time required to perform ICSI, meaning that IVF clinics can treat more patients, faster.
Male infertility is responsible for half of infertility cases worldwide. Around the world, sperm counts are dropping significantly and the demand for ICSI, the only treatment available for male infertility cases, is increasing rapidly.
ICSI–intracytoplasmic sperm injection– is a time-consuming and complicated process that requires preparing and injecting an individual sperm into each egg. Embryologists must undergo extensive training to learn to work with several tools under a microscope to perform ICSI, and even then, mistakes still happen.
See how microICSI works
Key Benefits
Why choose Fertilis?
Other companies have focused on improving embryo selection. Fertilis is focused on improving embryo quality. By mimicking nature and providing embryologists with new levels of precision and control, Fertilis’s devices remove variability, decrease human error, improve embryo quality, and increase IVF success rates.
Improving Success Rates
Devices that improve success rates, removing one of the cycles needed to get pregnant from the IVF journey.
Reducing Stress
Devices that standardize and automate IVF, reducing the risk of human error and decreasing stress on embryos and embryologists.
Mimicking Nature
Devices that enable dynamic cell culture, allowing for IVF to occur in an environment that more closely resembles the human body.
Fertilis is on a mission to eliminate infertility. We are making IVF more precise, affordable, and accessible. Our cutting-edge micro-fertility devices automate IVF, standardize lab procedures, and improve outcomes for patients and practitioners.
Our Partners
On our journey to eliminating infertility, we’ve partnered with the world’s best embryologists and IVF practitioners.
“Our application of micro-3D printing enables Fertilis to develop never-before-imagined medical devices for improving IVF results. Because of these outcomes, we have been able to attract partnerships with world leading clinics and IVF science royalty, who see what we are doing as the way forward to improve accessibility and results for their patients.”
Professor Jeremy Thompson
Chief Scientific Officer, Fertilis
Company
Our Team
Professor Jeremy Thompson is Co-Founder and Chief Scientific Officer at Fertilis. He invented the Fertilis devices after working in reproductive health for more than four decades.
Jeremy is an internationally recognised professor who has authored more than 200 journal articles. He has held leadership positions at the University’s Robinson Research Institute and the Australian Research Council’s Centre of Excellence for Nanoscale Biophotonics. From 1999 to 2004, he gained clinical experience serving as the director of IVF clinic Repromed.
He developed his commercialization experience through a ten-year partnership between The University of Adelaide, Cook Medical LLC, and Vrije Universiteit Brussel, Belgium. He has initiated a previous start-up, ART Lab Solutions Pty Ltd., and he was the commercialisation champion within the Robinson Research Institute.
Jeremy is a Fellow of the Society for Reproductive Biology, and in 2016, he was awarded its highest honor, The Founders Lecture. He holds a PhD in Veterinary Anatomy (Reproduction) from the University of Queensland.
Professor David Gardner (FAAS, AM) is a globally recognised IVF pioneer with considerable commercial experience in human ART, having developed the most successful culture system for the human embryo (G1/G2) and commercialized this system with Vitrolife AB in the late 1990s.
He is a Redmond Barry Distinguished Professor at the School of BioSciences, University of Melbourne, and has served as the Scientific Director of Melbourne IVF since 2017. David has made vast contributions to the field of reproductive biology, which were recognized in both his 2017 election into the Australian Academy of Science and his winning of the American Society of Reproductive Medicine’s highest honor, the Distinguished Researcher Award. In June 2022 he was awarded the “Order of Australia, AM” for “Service to Reproductive Medicine and Education.”
He has authored more than 300 publications, and he continues to lead innovation in human IVF. As the Scientific Director of Melbourne, he has run successful clinical trials in both embryo culture and the use of artificial intelligence in IVF.
David holds a PhD in Biological Sciences from the University of York, UK.
Marty Gauvin is CEO & Co-Founder of Fertilis, the medtech company making fertility treatment faster, cheaper, and more accessible for both clinics and patients.
A serial entrepreneur, Marty has previously founded eight start-ups– including medical assistance technology firm GCL Systems– which have collectively raised over $20M in private capital.
Since 2001, Marty has sat on the board of various government and private investment committees focused on increasing investment into the commercialization of Australian research, including the Investment Committee of Innovation and Science Australia which governs the venture capital sector in Australia and Young and Well CRC, Australia’s first Collaborative Research Centre exploring the role of technology in improving the mental health of young people.
Allison Love is Chief Product Engineering Officer at Fertilis where she leads on all aspects of product development, from manufacturing establishment to market release and production. Having held a variety of technical and managerial roles, Allison joined Fertilis in 2021, bringing over 20 years of experience in product engineering and development, specializing in in-vitro diagnostics (IVD) and delivering medical devices to market.
Prior to joining Fertilis, Allison successfully developed and managed award-winning products throughout their lifecycle, from concept prototyping to market launch and manufacturing sustainment. As the director of product development at Genea Biomedx, she led the IVF portfolio’s product development and engineering functions. At Leica Biosystems, a global leader in cancer diagnostics, Allison was program manager for their premium tissue processing platform, leading new product development and manufacturing sustainment. Previously, she was project leader and senior mechanical engineer at the consulting group Invetech, where she worked with health and life science leaders to develop breakthrough solutions, from life-saving point of care devices to diagnostics automation.
Allison holds a Bachelor of Engineering (Mech), Hons 1 from Monash University, Melbourne.
Roger Yerramsetti has more than 20 years of experience leading operational, innovation, and technology departments at ASX 100 companies, startups, and early-stage companies.
Roger has been working with Fertilis since 2019 when he began assessing and validating commercial opportunities, creating financial models, and proposing incremental prototype delivery to de-risk the business. He is a critical and creative thinker who solves business challenges by looking at them from multiple angles while staying close to the needs of the end user.
Hanna McLennan is leading the Adelaide-based embryological scientific discovery team.
Hanna completed a transdisciplinary project bridging across Reproductive Biology, Chemistry, and Physics as a PhD student of the Australian Research Council’s Centre of Excellence for Nanoscale BioPhotonics.
Hanna completed a transdisciplinary project bridging across Reproductive Biology, Chemistry, and Physics as a PhD student of the Australian Research Council’s Centre of Excellence for Nanoscale BioPhotonics.
With nine publications to her name, she is continuing her career with collaborations across disciplines within Fertilis to transition new discoveries to exciting applications within the IVF clinic.She holds a PhD in Medicine (Reproductive Biology) from the University of Adelaide.
Megan’s career spans more than 20 years as a clinical embryologist, scientific director, and laboratory quality officer. She has experience in seven high performing IVF laboratories and possesses excellent technical skills and international experience. She holds a Master of Clinical Embryology from Monash University.
At Fertilis, her skills and knowledge as a clinical research scientist are focused towards helping automate/simplify ICSI, IVF insemination techniques, and embryo culture.
Updates and Publications
Check out the latest updates and publications from Fertilis
Filter
More publications
Latest news
Fertilis is in the news. Below are some of our most recent mentions in the press.
